Brief: European Committee For Orphan Medicinal Products Provides Positive Opinion On Inovio's Application For Orphan Drug Designation For Ino-3107
26/04/2023 13:10
Inovio Pharmaceuticals Inc INO.O :
* EUROPEAN COMMITTEE FOR ORPHAN MEDICINAL PRODUCTS PROVIDES
POSITIVE OPINION ON INOVIO'S APPLICATION FOR ORPHAN DRUG
DESIGNATION FOR INO-3107
* INOVIO PHARMACEUTICALS INC- EUROPEAN COMMISSION FINAL
DECISION
ON INO-3107 ORPHAN DRUG DESIGNATION APPLICATION EXPECTED LATE
MAY 2023
Source text for Eikon: ID:nPn4cYttha
Further company coverage: INO.O
Recent news on Inovio Pharmaceuticals
See all newsBrief: Inovio Announces Favorable Judgment In Litigation With Vgxi, Inc. And Geneone Life Science
U.S. RESEARCH ROUNDUP-Airbnb, Five Below, Silgan Holdings
Inovio Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
Inovio Q2 net loss narrows on warrant gain, lower costs
Brief: Inovio Pharmaceuticals Q2 Operating Expenses USD 18.6 Million